Univest
Univest
  • Markets

Amrutanjan Health Care Q1 FY27 Results: Revenue Rs 102 Cr, PAT Rs 4 Cr and Key Highlights

  • August 12, 2026
  • Posted by: Lakshit Sharma
  • Category: News
No Comments

Amrutanjan Health Care Q1 FY27: Revenue Rs 102 Cr (+9.49% YoY). PAT Rs 4 Cr (-47.47% YoY). Results August 11, 2026. CMP Rs 535.

Amrutanjan Health Care Q1 FY27 results were announced on August 11, 2026, reporting a net profit (PAT) of Rs 4 crore, down 47.47% from Rs 8 crore in Q1 FY26. Revenue from operations grew 9.49% year on year to Rs 102 crore from Rs 94 crore in Q1 FY26. The Amrutanjan Health Care Q1 FY27 results are on a standalone basis for the quarter ended June 30, 2026.

Click Here – Get Free Investment Predictions

Table of Contents

Toggle
  • Amrutanjan Health Care Q1 FY27 Financial Highlights
  • Amrutanjan Health Care Q1 FY27 Performance Analysis
  • Key Business Factors in Amrutanjan Health Care Q1 FY27
    • 1. Revenue Trend Sets the Quarterly Context
    • 2. Gross Profit and Margin Movement
    • 3. Net Profit Outcome in the June Quarter
  • Dividend Details
  • Amrutanjan Health Care FY27 Outlook After Q1 Results
  • Amrutanjan Health Care Stock Performance
  • Key Risks to Watch After Amrutanjan Health Care Q1 FY27 Results
    • 1. Sector-Specific Demand Headwinds
    • 2. Input Cost and Margin Pressure
    • 3. Macroeconomic and Regulatory Uncertainty
  • Conclusion
  • Frequently Asked Questions on Amrutanjan Health Care Q1 FY27 Results
    • When were the Amrutanjan Health Care Q1 FY27 results announced?
    • What is the PAT in the Amrutanjan Health Care Q1 FY27 results?
    • What was the revenue in the Amrutanjan Health Care Q1 FY27 results?
    • Did Amrutanjan Health Care announce any dividend with the Q1 FY27 results?
    • What is the Amrutanjan Health Care FY27 outlook after Q1 results?
    • Is Amrutanjan Health Care a good buy after Q1 FY27 results?

Amrutanjan Health Care Q1 FY27 Financial Highlights

The table below summarises the key financial metrics from the Amrutanjan Health Care Q1 FY27 results compared with the same quarter of the previous year (Q1 FY26).

Metric Q1 FY27 (Jun 2026) Q1 FY26 (Jun 2025) YoY Change
Revenue from Operations (Rs Cr) Rs 102 Cr Rs 94 Cr +9.49%
Gross Profit (Rs Cr) Rs 4 Cr Rs 6 Cr -37.46%
Net Profit / (Loss) – PAT (Rs Cr) Rs 4 Cr Rs 8 Cr -47.47%

3 Stocks Building Serious Momentum Right Now

When Univest analysts identify high-conviction stock opportunities, investors pay attention.

Our research team has shortlisted the Top Stocks to Buy based on current market momentum, sector trends and growth potential for 2026.

  • Discover stocks investors are actively accumulating
  • High-conviction opportunities backed by research
  • Designed for the next phase of market growth

Unlock the latest Top Stock Picks on Univest

See the Stocks →

Amrutanjan Health Care Q1 FY27 Performance Analysis

Use the Univest Screener to Track Live Fundamentals of Indian Stocks

Amrutanjan health care q1 fy27 results show revenue growth of 9.49% year on year to Rs 102 crore. Gross profit declined to Rs 4 crore from Rs 6 crore in Q1 FY26.

Net profit in the June 2026 quarter stood at Rs 4 crore, a 47.47% decrease year on year. Investors tracking Amrutanjan Health Care quarterly results should verify these figures against the official BSE and NSE filings.

Key Business Factors in Amrutanjan Health Care Q1 FY27

1. Revenue Trend Sets the Quarterly Context

Revenue grew 9.49% year on year to Rs 102 crore, signalling steady demand conditions in the Healthcare and Consumer Health business.

2. Gross Profit and Margin Movement

Gross profit fell to Rs 4 crore from Rs 6 crore in Q1 FY26. Higher input costs or pricing pressure weighed on gross margins.

3. Net Profit Outcome in the June Quarter

PAT came in at Rs 4 crore, down 47.47% from Rs 8 crore in Q1 FY26. Consistent profitability will depend on revenue momentum and margin trends through FY27.

Dividend Details

No dividend has been declared alongside the Amrutanjan Health Care quarterly results for the quarter ended June 2026. Investors may track future announcements via BSE India and NSE India portals.

Amrutanjan Health Care FY27 Outlook After Q1 Results

Amrutanjan Health Care Q1 FY27 results set a broadly positive tone for the full financial year. Revenue grew 9.49% yoy to rs 102 crore from rs 94 crore a year earlier and a net profit (PAT) of Rs 4 crore provide a foundation for further improvement. Investors monitoring Amrutanjan Health Care Q1 results should track demand conditions in Healthcare and Consumer Health, input cost trajectories, and any capacity or business expansion announcements that could shape earnings through the remainder of FY27.

Amrutanjan Health Care Stock Performance

Download the Univest iOS App or Univest Android App to track Amrutanjan Health Care live share price and upcoming quarterly results.

Amrutanjan Health Care share price stood at Rs 535 on August 11, 2026, the day the quarterly results were declared. Post-results, the market will assess whether the Healthcare and Consumer Health company’s financial performance justifies the current valuation. Investors should verify the latest price and fundamentals on BSE and NSE before making any investment decision.

Key Risks to Watch After Amrutanjan Health Care Q1 FY27 Results

1. Sector-Specific Demand Headwinds

A slowdown in the Healthcare and Consumer Health sector could weigh on Amrutanjan Health Care revenue and profitability beyond what the June 2026 quarter already reflects.

2. Input Cost and Margin Pressure

Rising raw material or operational costs could compress gross margins and limit net profit recovery in subsequent quarters of FY27.

3. Macroeconomic and Regulatory Uncertainty

Inflation, interest rate movements, and regulatory changes remain key risks to the earnings trajectory of Amrutanjan Health Care through FY27.

Conclusion

Amrutanjan Health Care Q1 FY27 results report revenue of Rs 102 crore and a net profit (PAT) of Rs 4 crore, down 47.47% from Rs 8 crore in Q1 FY26. The June 2026 quarterly performance reflects the company’s position in the Healthcare and Consumer Health space. Investors should study the full financials on BSE and NSE and consult a SEBI-registered advisor before making any investment decision.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions on Amrutanjan Health Care Q1 FY27 Results

When were the Amrutanjan Health Care Q1 FY27 results announced?

Ans. The June 2026 quarterly results for Amrutanjan Health Care were announced on August 11, 2026, covering the quarter ended June 30, 2026. The standalone results were filed with BSE and NSE on the same date.

What is the PAT in the Amrutanjan Health Care Q1 FY27 results?

Ans. PAT (net profit) stood at Rs 4 crore in the June 2026 quarter, down 47.47% from Rs 8 crore in Q1 FY26.

What was the revenue in the Amrutanjan Health Care Q1 FY27 results?

Ans. Revenue for the June 2026 quarter rose 9.49% year on year to Rs 102 crore from Rs 94 crore in Q1 FY26.

Did Amrutanjan Health Care announce any dividend with the Q1 FY27 results?

Ans. No dividend has been declared alongside the June 2026 quarterly results. Investors may track future Amrutanjan Health Care dividend announcements through the BSE and NSE portals.

What is the Amrutanjan Health Care FY27 outlook after Q1 results?

Ans. The June 2026 quarterly performance signals a positive start to FY27 for Amrutanjan Health Care. Key factors to watch include revenue trends, margin performance, and Healthcare and Consumer Health sector demand through the rest of the financial year.

Is Amrutanjan Health Care a good buy after Q1 FY27 results?

Ans. The Q1 FY27 financial performance of Amrutanjan Health Care reflects challenging trends in the June 2026 quarter. This article is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered investment advisor.



News

Leave a Reply Cancel reply